Debate Over Funding for Friedreich’s Ataxia Drug in Ireland

A new drug for Friedreich’s ataxia is recommended against funding by the NCPE due to its high cost versus benefits, sparking debate on its availability.

24 Aug, 04:30 — 24 Aug, 04:30

Post Share

Sources

Showing 1 of 1 sources

irish-independent1d ago

Luke O’Neill: Friedreich’s ataxia drug far from silver bullet, but it's the best option and should be funded

NCPE has recommended against paying for the treatment, because of its very high cost weighed against the benefits it brings

By Luke O'Neill

Read full article →

PERSPECTA

PERSPECTA

Debate Over Funding for Friedreich’s Ataxia Drug in Ireland

Sources

Luke O’Neill: Friedreich’s ataxia drug far from silver bullet, but it's the best option and should be funded

Related Stories

Trump Administration Plans Mass Visa Revocations for Asylum Seekers

Pakistan and Iran Make Progress in De-escalation Talks

Zelensky Appeals to EU for More Financial Aid and Advance Payments for Ukraine

Slovak Prime Minister Fico Announces Abolition of Transaction Tax

PERSPECTA